Takeaways from #ACC2024. Late breaking trials - take home points @ACCinTouch

1. RELIEVE-HF Trial: In patients with HFrEF and HFpEF, Interatrial Shunt did not show any significant difference in the primary effectiveness endpoint, a composite of all-cause mortality, LVAD/heart transplantation, HF hospitalizations, outpatient worsening HF events. 2. EMPACT-MI Trial: Among patients at increased risk for HF after acute MI, treatment with empagliflozin did not lead to a significantly lower risk of a first hospitalization for HF or death from any cause than placebo.